Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $130.00 at HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH) had its price objective hoisted by equities research analysts at HC Wainwright from $47.00 to $130.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 69.50% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Oppenheimer restated an “outperform” rating and set a $145.00 price objective on shares of Dianthus Therapeutics in a report on Monday. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research note on Monday. Wedbush upped their price target on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Finally, Jefferies Financial Group lifted their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday, February 2nd. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $96.78.

Dianthus Therapeutics Stock Up 17.6%

Shares of DNTH stock traded up $11.50 during trading on Monday, reaching $76.70. 3,006,667 shares of the company’s stock were exchanged, compared to its average volume of 870,649. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $84.86. The stock has a market capitalization of $3.31 billion, a PE ratio of -22.10 and a beta of 1.56. The firm’s fifty day moving average price is $48.42 and its 200-day moving average price is $40.78.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The firm had revenue of $0.57 million for the quarter, compared to analyst estimates of $0.40 million. As a group, analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Dianthus Therapeutics

Several large investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after acquiring an additional 618 shares in the last quarter. Ensign Peak Advisors Inc acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at $2,504,000. American Century Companies Inc. lifted its holdings in Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares in the last quarter. XTX Topco Ltd acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth $503,000. Finally, Sio Capital Management LLC grew its holdings in shares of Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after buying an additional 119,073 shares in the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Dianthus Therapeutics

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Dianthus announced an early GO decision in the Phase 3 CAPTIVATE trial after meeting responder criteria (20 confirmed responders) with fewer than the planned participants — company will keep the 300mg S.C. Q2W dose and plans to discuss removing the 600mg dose with regulators. This is the main catalyst driving the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: The company highlighted the GO decision and Q4/FY results in its investor release, stressing that key CAPTIVATE objectives were achieved ahead of Q2 guidance. Highlights Recent Business Achievements
• Positive Sentiment: Dianthus scheduled a conference call/webcast to discuss the interim responder analysis — management access and Q&A typically help reinforce investor confidence after trial readouts. Conference Call & Webcast Announcement
• Positive Sentiment: Truist raised its price target from $63 to $110 and maintained a Buy — analyst upgrade/target lift provides third-party validation and likely supported the share uptick. Benzinga PT Raise
• Positive Sentiment: Press and commentary noted the stock’s strong multi-year appreciation and tied the surge to the CIDP readout — momentum and positive narrative amplified buying. Investors.com: What’s Going On?
• Neutral Sentiment: Valuation commentary and analyst write-ups are evaluating DNTH after a strong run; these pieces frame potential upside but don’t change clinical facts. Yahoo Finance Valuation Piece
• Negative Sentiment: Q4 results: Dianthus reported a larger-than-expected loss (EPS -$1.43 vs. consensus ~ -$0.97) and extremely negative margins/ROE — the miss is a near-term financial headwind and explains some profit-taking pressure. Zacks: Q4 Loss, Miss

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.